Next Article in Journal / Special Issue
Faecal Microbiota Are Related to Insulin Sensitivity and Secretion in Overweight or Obese Adults
Previous Article in Journal
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
Previous Article in Special Issue
Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes
Article Menu

Export Article

Open AccessArticle
J. Clin. Med. 2019, 8(4), 451; https://doi.org/10.3390/jcm8040451

H. pylori Eradication Treatment Alters Gut Microbiota and GLP-1 Secretion in Humans

1
Department of Endocrinology and Nutrition, Virgen de la Victoria Hospital (IBIMA), Malaga University, 29010 Malaga, Spain
2
Centro de Investigacion Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN CB06/003), Instituto de Salud Carlos III, 28029 Madrid, Spain
3
Department of Endocrinology and Nutrition, Puerta del Mar University Hospital, 11009 Cadiz, Spain
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this study.
Received: 3 March 2019 / Revised: 26 March 2019 / Accepted: 30 March 2019 / Published: 4 April 2019
(This article belongs to the Special Issue Type 2 Diabetes: Update on Pathophysiology and Treatment)
  |  
PDF [1874 KB, uploaded 4 April 2019]
  |  

Abstract

Changes in the intestinal microbial community and some metabolic disturbances, including obesity and type2 diabetes, are related. Glucagon-like peptide-1 (GLP-1) regulates glucose homeostasis. Microbiota have been linked to incretin secretion. Antibiotic use causes changes in microbial diversity and composition. Our aim was to evaluate the relationship between microbiota changes and GLP-1 secretion. A prospective case-control study with a Helicobacter pylori-positive patient model involving subjects under eradication therapy (omeprazole, clarithromycin, and amoxicillin). Forty patients with H. pylori infection and 20 matched participants, but negative for H. pylori antigen. Patients were evaluated before and two months after treatment. We analyzed anthropometric measurements, carbohydrate metabolism, lipid profile, and C-reactive protein. Gut microbiota composition was analyzed through 16S rRNA amplicon sequencing (IlluminaMiSeq). Eradication treatment for H. pylori decreased bacterial richness (Chao1, p = 0.041). Changes in gut microbiota profiles were observed at phylum, family, genus and species levels. GLP-1 secretion and variables of carbohydrate metabolism were improved. Correlations were seen between GLP-1 changes and variations within microbial community abundances, specifically Bifidobacterium adolescentis, the Lachnobacterium genus, and Coriobacteriaceae family. A conventional treatment to eradicate H. pylori could improve carbohydrate metabolism possibly in relation with an increase in GLP-1 secretion. GLP-1 secretion may be related to alterations in intestinal microbiota, specifically Lachnobacterium, B. adolescentis and Coriobacteriaceae. View Full-Text
Keywords: GLP-1 secretion; gut microbiota; antibiotic; H. pylori GLP-1 secretion; gut microbiota; antibiotic; H. pylori
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Cornejo-Pareja, I.; Martín-Núñez, G.M.; Roca-Rodríguez, M.M.; Cardona, F.; Coin-Aragüez, L.; Sánchez-Alcoholado, L.; Gutiérrez-Repiso, C.; Muñoz-Garach, A.; Fernández-García, J.C.; Moreno-Indias, I.; Tinahones, F.J. H. pylori Eradication Treatment Alters Gut Microbiota and GLP-1 Secretion in Humans. J. Clin. Med. 2019, 8, 451.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top